# Orchestra BioMed Holdings, Inc.: overview OBIO · Nasdaq · CIK 1814114 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/obio.md) · [Financials](/companies/obio/financials.md) · [Filings](/companies/obio/filings.md) · [Insiders](/companies/obio/insiders.md) Latest reported revenue: [$88.0k](/filings/0001104659-26-093357.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-093357). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.0](/filings/0001104659-25-109128.md) | [0.3 d](/filings/0001104659-26-026754.md) | [0.9](/filings/0001104659-26-059382.md) | [0.8](/filings/0001104659-26-093357.md) | [0.9](/filings/0001104659-25-109128.md) | [30.9 d](/filings/0001104659-26-026754.md) | [0.1](/filings/0001104659-26-059382.md) | [0.1](/filings/0001104659-26-093357.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1655.7%)](/filings/0001104659-25-109128.md) | [(6591.7%) d](/filings/0001104659-26-026754.md) | [(2179.8%)](/filings/0001104659-26-059382.md) | [(2311.8%)](/filings/0001104659-26-093357.md) | [(2359.2%)](/filings/0001104659-25-109128.md) | [21.8% d](/filings/0001104659-26-026754.md) | [(20069.1%)](/filings/0001104659-26-059382.md) | [(25404.5%)](/filings/0001104659-26-093357.md) | | Net margin | % | [(1562.9%)](/filings/0001104659-25-109128.md) | [(6385.4%) d](/filings/0001104659-26-026754.md) | [(2160.7%)](/filings/0001104659-26-093357.md) | [(2316.1%)](/filings/0001104659-26-093357.md) | [(2419.0%)](/filings/0001104659-25-109128.md) | [20.2% d](/filings/0001104659-26-026754.md) | [(18810.0%)](/filings/0001104659-26-093357.md) | [(26994.3%)](/filings/0001104659-26-093357.md) | | Diluted EPS | $ per share | [(0.41)](/filings/0001104659-25-109128.md) | not reported | [(0.49)](/filings/0001104659-26-059382.md) | [(0.50)](/filings/0001104659-26-093357.md) | [(0.40)](/filings/0001104659-25-109128.md) | not reported | [(0.33)](/filings/0001104659-26-059382.md) | [(0.38)](/filings/0001104659-26-093357.md) | | Free cash flow | $m | [(13.8) d](/filings/0001104659-25-109128.md) | [(13.6) d](/filings/0001104659-26-026754.md) | [(16.7)](/filings/0001104659-26-059382.md) | [(15.6) d](/filings/0001104659-26-093357.md) | [(14.9) d](/filings/0001104659-25-109128.md) | [(2.3) d](/filings/0001104659-26-026754.md) | [(22.4)](/filings/0001104659-26-059382.md) | [(19.6) d](/filings/0001104659-26-093357.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [3.5](/filings/0001558370-24-004083.md) | [2.8](/filings/0001558370-25-004161.md) | [2.6](/filings/0001104659-26-026754.md) | [33.5](/filings/0001104659-26-026754.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(924.3%)](/filings/0001558370-24-004083.md) | [(1866.2%)](/filings/0001558370-25-004161.md) | [(2437.5%)](/filings/0001104659-26-026754.md) | [(154.7%)](/filings/0001104659-26-026754.md) | | Net margin | % | not reported | [(951.3%)](/filings/0001558370-24-004083.md) | [(1779.7%)](/filings/0001558370-25-004161.md) | [(2313.3%)](/filings/0001104659-26-026754.md) | [(157.4%)](/filings/0001104659-26-026754.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001213900-23-005085.md) | [(2.24)](/filings/0001558370-24-004083.md) | [(1.48)](/filings/0001558370-25-004161.md) | [(1.66)](/filings/0001104659-26-026754.md) | [(1.11)](/filings/0001104659-26-026754.md) | | Free cash flow | $m | not reported | [(29.9)](/filings/0001558370-24-004083.md) | [(46.2)](/filings/0001558370-25-004161.md) | [(50.8)](/filings/0001104659-26-026754.md) | [(49.5)](/filings/0001104659-26-026754.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/obio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $41.2m | 9,556,063 | | Added +1,250,000 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $21.7m | 5,037,906 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.8m | 2,510,387 | | Added +1,874,673 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.7m | 2,022,916 | | Reduced −181,403 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.4m | 1,007,908 | | Added +522,416 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $4.3m | 1,000,000 | | Unchanged | | [Propel Bio Management, LLC](/funds/1969764.md) | 2026-06-30 | $3.9m | 896,701 | | Unchanged | | [UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC](/funds/861177.md) | 2026-06-30 | $2.8m | 642,154 | | New +642,154 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.2m | 516,050 | | Added +346,640 | | [RICE HALL JAMES & ASSOCIATES, LLC](/funds/1230765.md) | 2026-06-30 | $1.8m | 424,000 | | Added +404,999 | ## Recent filings [All 406 filings](/companies/obio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 12:14 ET | [8-K](/filings/0001104659-26-112586.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-112586 | | 2026-09-08 | 13:30 ET | [8-K](/filings/0001104659-26-105733.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-105733 | | 2026-08-10 | 20:07 ET | [10-Q](/filings/0001104659-26-093357.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093357 | | 2026-06-23 | 20:52 ET | [8-K](/filings/0001104659-26-076845.md) | 5.07 Shareholder vote results | 0001104659-26-076845 | | 2026-05-12 | 20:07 ET | [10-Q](/filings/0001104659-26-059382.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059382 | | 2026-04-29 | 21:37 ET | [SCHEDULE 13D/A](/filings/0001493215-26-000068.md) | Ownership report, active investor, amended | 0001493215-26-000068 | | 2026-04-29 | 20:30 ET | [DEF 14A](/filings/0001104659-26-051570.md) | Proxy statement, period 2026-06-23 | 0001104659-26-051570 | | 2026-03-12 | 12:03 ET | [10-K](/filings/0001104659-26-026754.md) | Annual report, period 2025-12-31 | 0001104659-26-026754 | | 2026-02-25 | 21:28 ET | [SCHEDULE 13D/A](/filings/0001493215-26-000063.md) | Ownership report, active investor, amended | 0001493215-26-000063 | | 2026-02-13 | 22:00 ET | [8-K](/filings/0001104659-26-015315.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-015315 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-026754.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/fd0dda93-fd2f-4aa6-a655-896fac234e30) ## About the filer - CIK: 1814114 - Tickers: OBIO - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.